Preliminary injunction appeal to have big impact on US biosimilars litigation

Preliminary injunction appeal to have big impact on US biosimilars litigation

The Herceptin patent dispute between Genentech and Amgen is a much watch for biologics producers and their counsel

Unlock unlimited access to all IAM content